ClinicalTrials.gg
CompletedNCT03250273Updated May 28, 2025Results posted

A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma

A Phase 2 interventional study of Entinostat and Nivolumab in Metastatic Cholangiocarcinoma, Cholangiocarcinoma and Pancreatic Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-28.

Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 328 studies in Cholangiocarcinoma with a site in United States — 72 open to participants now, 109 under way, 7 of them phase 3. Cholangiocarcinoma · United States.

Enrollment
139th of 279
44 · median 44
Started
2017
with 25 others
Phase 2
94 of 328
20 open now
Registered
123rd of 328
by date

Among the 328 studies in Cholangiocarcinoma with a site in United States, this one is the 139th largest by enrollment of the 279 interventional ones that give a count, is one of 26 that started in 2017, is one of 94 in phase 2, and was the 123rd registered.

Cholangiocarcinoma

825 studies on the registry are indexed under Cholangiocarcinoma; 288 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

72 of the 328 studies in Cholangiocarcinoma with a site in United States are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 328 studies in Cholangiocarcinoma with a site in United States, or all of them as a file.
02

Study summary

The proposed study is an open-label, two-arm study of entinostat plus nivolumab in patients with unresectable or metastatic cholangiocarcinoma (CCA) or pancreatic ductal adenocarcinoma (PDAC).

03

Conditions studied

  • Metastatic Cholangiocarcinoma
  • Cholangiocarcinoma
  • Pancreatic Cancer
  • Metastatic Pancreatic Cancer
  • Unresectable Pancreatic Cancer
  • Unresectable Cholangiocarcinoma

Keywords

  • Immunotherapy
  • Nivolumab
  • Entinostat
  • Pancreatic Adenocarcinoma
  • Cholangiocarcinoma
  • Unresectable
  • Metastatic
  • PD-1
  • Antibody
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years.
  2. Have or cytologically proven cholangiocarcinoma or adenocarcinoma of the pancreas that is or unresectable.
  3. (ECOG) performance status 0 or 1
  4. of greater than 12 weeks.
  5. Patients must have adequate organ and marrow function defined by study-specified laboratory tests.
  6. Woman of child bearing potential must have a negative pregnancy test.
  7. Must have progressive .
  8. Must have an accessible non-bone tumor that can be biopsied.
  9. Must use acceptable form of while on study.
  10. Willing to provide tissue and blood samples.
  11. Ability to understand and willingness to sign a written document.

Exclusion criteria

Exclusion Criteria:

  1. Chemotherapy, radiotherapy, therapy, or surgery less than 3 weeks prior to trial registration
  2. Prior treatment with epigenetic therapy (such as entinostat, panobinostat, vorinostat, romidepsin, 5-azacitidine, or decitabine)
  3. Prior treatment with immunotherapy agents (including, , anti-PD-L1, anti-PD-L2, anti-CTLA4, etc.).
  4. reaction to any monoclonal antibody.
  5. History of any disease: inflammatory bowel disease, (including ulcerative colitis and Crohn's Disease), rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus (SLE) autoimmune vasculitis (e.g., Wegener's Granulomatosis), central nervous system (CNS) or motor neuropathy considered to be of autoimmune origin (e.g., Guillain-Barre Syndrome, Myasthenia Gravis, Multiple Sclerosis). Patients are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (precipitating event).
  6. Have significant and/or malignant pleural effusion
  7. Has a pulse oximetry \< 92% on room air.
  8. Known history or evidence of .
  9. Conditions, including alcohol or drug dependence, intercurrent illness, or lack of sufficient peripheral venous access, that would affect the patient's ability to comply with study visits and procedures.
  10. Are pregnant or breastfeeding.
  11. Infection with or or C.
  12. Patients on agents.
  13. Requiring concurrent administration of valproic acid.
  14. Patients with diverticulitis, intra-abdominal abscess, or GI obstruction
  15. Any to oral agents.
  16. Another active ≤ 3 years prior to registration with the exception of non-melanotic skin cancer or carcinoma-in-situ of any type.
  17. Unwilling or unable to follow the study schedule for any reason.
  18. Evidence of ascites on imaging.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Arm A - Cholangiocarcinoma

    Drug: Entinostat · Drug: Nivolumab

  • Experimental
    ARM B - Pancreatic Cancer

    Drug: Entinostat · Drug: Nivolumab

Interventions

  • Entinostat (5mg) will be administered starting with 2 lead-in doses at 14 and 7 days before the first dose of nivolumab in combination with entinostat. After the lead-in dose, entinostat will be administered once a week (days 1, 8, 15, and 21 of each treatment cycle).

    Also known as: SNDX-275

  • After both lead-in doses of entinostat, nivolumab (240 mg) will be administered every 2 weeks (day 1 and day 15 of a cycle).

    Also known as: OPDIVO, BMS-936558, MDX1106, ONO-4538

  • Entinostat (5mg) will be administered starting with 2 lead-in doses at 14 and 7 days before the first dose of nivolumab in combination with entinostat. After the lead-in dose, entinostat will be administered once a week (days 1, 8, 15, and 21 of each treatment cycle).

    Also known as: SNDX-275

  • After both lead-in doses of entinostat, nivolumab (240 mg) will be administered every 2 weeks (day 1 and day 15 of a cycle).

    Also known as: OPDIVO, BMS-936558, MDX1106, ONO-4538

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR) Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1)

    Objective Response Rate (ORR) is defined as the number of patients achieving a complete response (CR) or partial response (PR) based on RECIST 1.1 criteria. CR = disappearance of all target lesions, PR is =\>30% decrease in sum of diameters of target lesions. Subjects who discontinue due to clinical progression prior to post-baseline tumor assessments were considered as non-responders.

    Time frame: 27 months

Secondary outcomes

  1. Number of Patients Experiencing a Grade 3 or Above Treatment-related Adverse Event (AE)

    When calculating the incidence of AEs, each AE (as defined by NCI CTCAE v4.03) will be counted only once for a given subject.

    Time frame: 29 months

  2. Overall Survival (OS)

    OS is defined as the duration of time from start of study treatment to time of death (OS will be censored on the date the subject was last known to be alive for subjects without documentation of death at the time of analysis). Estimation based on the Kaplan-Meier curve.

    Time frame: 38 months

  3. Overall Survival (OS) at 6 Months

    OS is defined as the proportion of subjects who are alive at 6 months. Estimation based on the Kaplan-Meier curve.

    Time frame: 6 months

  4. Overall Survival (OS) at 12 Months

    OS is defined as the proportion of subjects who are alive at 12 months. Estimation based on the Kaplan-Meier curve.

    Time frame: 12 months

  5. Overall Survival (OS) at 24 Months

    OS is defined as the proportion of subjects who are alive at 24 months. Estimation based on the Kaplan-Meier curve.

    Time frame: 24 months

  6. Overall Survival (OS) at 36 Months

    OS is defined as the proportion of subjects who are alive at 36 months. Estimation based on the Kaplan-Meier curve.

    Time frame: 36 months

  7. Duration of Response (DOR)

    Duration of response (DOR) will be calculated for subjects who achieve a best overall response of CR or PR. DOR is defined as the number of months from the start date of PR or CR (whichever response is recorded first) and subsequently confirmed to the first date that recurrent or progressive disease or death is documented. Per RECIST 1.1 criteria, CR = disappearance of all target lesions, Partial Response (PR) is =\>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is \>20% increase in sum of diameters of target lesions.

    Time frame: 27 months

  8. Progression Free Survival (PFS) at 6 Months

    PFS is defined as the proportion of patients without disease progression (PD or relapse from CR) or death due to any cause at 6 months. Disease progression will be assessed using RECIST (version 1.1). Per RECIST 1.1 criteria, CR = disappearance of all target lesions, Partial Response (PR) is =\>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is \>20% increase in sum of diameters of target lesions, Stable Disease (SD) is \<30% decrease or \<20% increase in sum of diameters of target lesions.Estimation based on the Kaplan-Meier curve.

    Time frame: 6 months

  9. Progression Free Survival (PFS) at 12 Months

    PFS is defined as the proportion of patients without disease progression (PD or relapse from CR) or death due to any cause at 12 months. Disease progression will be assessed using RECIST (version 1.1). Per RECIST 1.1 criteria, CR = disappearance of all target lesions, Partial Response (PR) is =\>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is \>20% increase in sum of diameters of target lesions, Stable Disease (SD) is \<30% decrease or \<20% increase in sum of diameters of target lesions.Estimation based on the Kaplan-Meier curve.

    Time frame: 12 months

  10. Progression Free Survival (PFS) at 24 Months

    PFS is defined as the proportion of patients without disease progression (PD or relapse from CR) or death due to any cause at 24 months. Disease progression will be assessed using RECIST (version 1.1). Per RECIST 1.1 criteria, CR = disappearance of all target lesions, Partial Response (PR) is =\>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is \>20% increase in sum of diameters of target lesions, Stable Disease (SD) is \<30% decrease or \<20% increase in sum of diameters of target lesions.Estimation based on the Kaplan-Meier curve.

    Time frame: 24 months

07

Results

Posted Dec 16, 2021

Participant flow

Participant flow — Overall Study
MilestoneArm A - CholangiocarcinomaARM B - Pancreatic Cancer
Started1330
Completed1118
Not completed212
Withdrew: Disease progression211
Withdrew: Death01

Outcome measures

PrimaryObjective Response Rate (ORR) Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1)

Objective Response Rate (ORR) is defined as the number of patients achieving a complete response (CR) or partial response (PR) based on RECIST 1.1 criteria. CR = disappearance of all target lesions, PR is =\>30% decrease in sum of diameters of target lesions. Subjects who discontinue due to clinical progression prior to post-baseline tumor assessments were considered as non-responders.

Time frame:
27 months
Reported as:
Count of participants · Participants
Objective Response Rate (ORR) Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1)
ParticipantsArm A - CholangiocarcinomaARM B - Pancreatic Cancer
Objective Response Rate (ORR) Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1)03
SecondaryNumber of Patients Experiencing a Grade 3 or Above Treatment-related Adverse Event (AE)

When calculating the incidence of AEs, each AE (as defined by NCI CTCAE v4.03) will be counted only once for a given subject.

Time frame:
29 months
Reported as:
Count of participants · Participants
Number of Patients Experiencing a Grade 3 or Above Treatment-related Adverse Event (AE)
ParticipantsArm A - CholangiocarcinomaARM B - Pancreatic Cancer
Number of Patients Experiencing a Grade 3 or Above Treatment-related Adverse Event (AE)519
SecondaryOverall Survival (OS)

OS is defined as the duration of time from start of study treatment to time of death (OS will be censored on the date the subject was last known to be alive for subjects without documentation of death at the time of analysis). Estimation based on the Kaplan-Meier curve.

Time frame:
38 months
Reported as:
Median · months
Overall Survival (OS)
monthsArm A - CholangiocarcinomaARM B - Pancreatic Cancer
Overall Survival (OS)6.378 (3.748 to NA)2.729 (1.84 to 5.62)
SecondaryOverall Survival (OS) at 6 Months

OS is defined as the proportion of subjects who are alive at 6 months. Estimation based on the Kaplan-Meier curve.

Time frame:
6 months
Reported as:
Number · proportion of participants
Overall Survival (OS) at 6 Months
proportion of participantsArm A - CholangiocarcinomaARM B - Pancreatic Cancer
Overall Survival (OS) at 6 Months0.538 (0.326 to 0.891)0.277 (0.153 to 0.498)
SecondaryOverall Survival (OS) at 12 Months

OS is defined as the proportion of subjects who are alive at 12 months. Estimation based on the Kaplan-Meier curve.

Time frame:
12 months
Reported as:
Number · proportion of participants
Overall Survival (OS) at 12 Months
proportion of participantsArm A - CholangiocarcinomaARM B - Pancreatic Cancer
Overall Survival (OS) at 12 Months0.308 (0.136 to 0.695)0.138 (0.056 to 0.343)
SecondaryOverall Survival (OS) at 24 Months

OS is defined as the proportion of subjects who are alive at 24 months. Estimation based on the Kaplan-Meier curve.

Time frame:
24 months
Reported as:
Number · proportion of participants
Overall Survival (OS) at 24 Months
proportion of participantsArm A - CholangiocarcinomaARM B - Pancreatic Cancer
Overall Survival (OS) at 24 Months0.077 (0.012 to 0.506)0.035 (0.005 to 0.237)
SecondaryOverall Survival (OS) at 36 Months

OS is defined as the proportion of subjects who are alive at 36 months. Estimation based on the Kaplan-Meier curve.

Time frame:
36 months
Reported as:
Number · proportion of participants
Overall Survival (OS) at 36 Months
proportion of participantsArm A - CholangiocarcinomaARM B - Pancreatic Cancer
Overall Survival (OS) at 36 Months0.077 (0.012 to 0.506)0.035 (0.005 to 0.237)
SecondaryDuration of Response (DOR)

Duration of response (DOR) will be calculated for subjects who achieve a best overall response of CR or PR. DOR is defined as the number of months from the start date of PR or CR (whichever response is recorded first) and subsequently confirmed to the first date that recurrent or progressive disease or death is documented. Per RECIST 1.1 criteria, CR = disappearance of all target lesions, Partial Response (PR) is =\>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is \>20% increase in sum of diameters of target lesions.

Time frame:
27 months
Reported as:
Median · months
Duration of Response (DOR)
monthsArm A - CholangiocarcinomaARM B - Pancreatic Cancer
Duration of Response (DOR)—10.2 (3.7 to 17.9)
SecondaryProgression Free Survival (PFS) at 6 Months

PFS is defined as the proportion of patients without disease progression (PD or relapse from CR) or death due to any cause at 6 months. Disease progression will be assessed using RECIST (version 1.1). Per RECIST 1.1 criteria, CR = disappearance of all target lesions, Partial Response (PR) is =\>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is \>20% increase in sum of diameters of target lesions, Stable Disease (SD) is \<30% decrease or \<20% increase in sum of diameters of target lesions.Estimation based on the Kaplan-Meier curve.

Time frame:
6 months
Reported as:
Number · proportion of participants
Progression Free Survival (PFS) at 6 Months
proportion of participantsArm A - CholangiocarcinomaARM B - Pancreatic Cancer
Progression Free Survival (PFS) at 6 Months0 (NA to NA)0.067 (0.017 to 0.254)
SecondaryProgression Free Survival (PFS) at 12 Months

PFS is defined as the proportion of patients without disease progression (PD or relapse from CR) or death due to any cause at 12 months. Disease progression will be assessed using RECIST (version 1.1). Per RECIST 1.1 criteria, CR = disappearance of all target lesions, Partial Response (PR) is =\>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is \>20% increase in sum of diameters of target lesions, Stable Disease (SD) is \<30% decrease or \<20% increase in sum of diameters of target lesions.Estimation based on the Kaplan-Meier curve.

Time frame:
12 months
Reported as:
Number · proportion of participants
Progression Free Survival (PFS) at 12 Months
proportion of participantsArm A - CholangiocarcinomaARM B - Pancreatic Cancer
Progression Free Survival (PFS) at 12 Months0 (NA to NA)0.067 (0.017 to 0.254)
SecondaryProgression Free Survival (PFS) at 24 Months

PFS is defined as the proportion of patients without disease progression (PD or relapse from CR) or death due to any cause at 24 months. Disease progression will be assessed using RECIST (version 1.1). Per RECIST 1.1 criteria, CR = disappearance of all target lesions, Partial Response (PR) is =\>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is \>20% increase in sum of diameters of target lesions, Stable Disease (SD) is \<30% decrease or \<20% increase in sum of diameters of target lesions.Estimation based on the Kaplan-Meier curve.

Time frame:
24 months
Reported as:
Number · proportion of participants
Progression Free Survival (PFS) at 24 Months
proportion of participantsArm A - CholangiocarcinomaARM B - Pancreatic Cancer
Progression Free Survival (PFS) at 24 Months0 (NA to NA)0 (NA to NA)

Adverse events

Collected over 29 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A - Cholangiocarcinoma0/13 (0%)4/13 (30.8%)12/13 (92.3%)
ARM B - Pancreatic Cancer1/30 (3.3%)3/30 (10%)27/30 (90%)
Most frequent serious events
Most frequent serious events
EventArm A - CholangiocarcinomaARM B - Pancreatic Cancer
PneumonitisInfections and infestations2/130/30
ColitisGastrointestinal disorders1/131/30
PneumoniaInfections and infestations1/130/30
TransaminitisInvestigations1/130/30
Renal tubular acidosisMetabolism and nutrition disorders0/131/30
ArthritisMusculoskeletal and connective tissue disorders0/131/30
Most frequent other events
Showing 10 of 29
Most frequent other events
EventArm A - CholangiocarcinomaARM B - Pancreatic Cancer
FatigueGeneral disorders12/1320/30
AnorexiaMetabolism and nutrition disorders5/1315/30
NauseaGastrointestinal disorders6/1310/30
EdemaGeneral disorders4/134/30
AnemiaBlood and lymphatic system disorders1/139/30
Lymphocyte count decreasedInvestigations2/138/30
Platelet count decreasedInvestigations3/133/30
Rash maculo-papularSkin and subcutaneous tissue disorders3/134/30
VomitingGastrointestinal disorders0/136/30
HyponatremiaMetabolism and nutrition disorders1/135/30

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm A - CholangiocarcinomaARM B - Pancreatic CancerTotal
<=18 years000
Between 18 and 65 years101626
>=65 years31417
Sex: Female, Male
Sex: Female, Male(Participants)Arm A - CholangiocarcinomaARM B - Pancreatic CancerTotal
Female41317
Male91726
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A - CholangiocarcinomaARM B - Pancreatic CancerTotal
Hispanic or Latino112
Not Hispanic or Latino112738
Unknown or Not Reported123
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A - CholangiocarcinomaARM B - Pancreatic CancerTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American022
White122840
More than one race000
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(Participants)Arm A - CholangiocarcinomaARM B - Pancreatic CancerTotal
United States133043
08

Study locations

1 site
  • Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland 21231, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Nov 2020, 36 months.

Results were first posted in Dec 2021, 1 year after primary completion.

Of 147 non-industry phase 2 interventional studies under Cholangiocarcinoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 65. This study's 36 months is below that.

Counting every sponsor, half of 173 studies reached it within 46 months; a quarter within 29 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2017
First posted
Aug 15, 2017
StartActual
Nov 6, 2017
Primary completionActual
Nov 20, 2020
CompletionActual
Nov 20, 2020
Results first posted
Dec 16, 2021
Last update
May 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03250273
Responsible party
Sponsor
First posted
Aug 15, 2017
Start date
Nov 6, 2017
Primary completion
Nov 20, 2020
Completion
Nov 20, 2020
Results posted
Dec 16, 2021
Last update
May 28, 2025

Study contacts

Nilofer Azad, MD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Entinostat

Start the discussion